Search

A recent report from researchers at Nanjing Drum Tower Hospital in China discusses the use of hierarchically structured hydrogel-encapsulated mesoporous silica nanocarriers (MSNs) to deliver galantamine hydrobromide (GAH) for the treatment of Alzheimer's disease (AD). GAH is an approved medication for AD, but it can cause side effects such as nausea and poor patient compliance. The researchers propose that using hydrogel-encapsulated MSNs can minimize these adverse reactions and improve drug delivery efficiency. They believe that this technology has the potential to significantly impact clinical treatment. [Extracted from the article]

Researchers from Urmia University have conducted a study on nanocarriers and their interactions with memantine, rivastigmine, beta-amyloid structures, and graphene oxide. The goal of the study was to enhance drug development through computational techniques. The results showed that memantine had a more stable complex with graphene oxide compared to rivastigmine, suggesting a stronger binding affinity. This research provides valuable insights into potential therapeutic strategies for Alzheimer's disease. [Extracted from the article]

A recent study conducted by researchers at Chonnam National University in South Korea explored the potential cognitive benefits of Agastache rugosa, a traditional Asian herbal medicine primarily used for digestive problems. The study found that an extract of A. rugosa demonstrated significant antioxidant and anti-inflammatory effects, as well as improved memory performance in mice with scopolamine-induced memory impairment. The extract also showed modulation of the cholinergic system and increased hippocampal neurogenesis, suggesting its potential use as a cognitive enhancer. This research provides valuable insights into the potential therapeutic applications of A. rugosa in addressing cognitive decline. [Extracted from the article]

A recent study conducted at Government College University in Faisalabad, Pakistan, explored the use of nonionic surfactants for the solubilization and delivery of the nootropic drug piracetam. The researchers developed a cluster of micelles using Tween 80 and Triton-X 100 surfactants, and investigated the drug-surfactant interaction in different mediums. The results showed that the solubilization of piracetam was enhanced by mixing an appropriate amount of both surfactants, and the micellar formulations were stable. This research provides insights into the development of nanopharmaceuticals for drug delivery. [Extracted from the article]

A recent study investigated the awareness and use of the prescription drug modafinil among medical students. The study found that many participants reported using modafinil to enhance attention, focus, productivity, and exam performance. While some users found the drug effective, others experienced negative effects. The study highlights the need for comprehensive advice and policies to support students and mitigate the risks associated with the use of modafinil. However, the low response rate of the survey suggests that alternative methods should be employed to investigate drug use related topics. [Extracted from the article]

A recent study conducted by researchers at Frederick University in Nicosia, Cyprus, explored the potential of certain compounds to act as antioxidants and/or anti-inflammatory agents. The study focused on the development of multi-targeting molecules that could be used to combat degenerative conditions such as Alzheimer's disease and Parkinson's disease. The researchers designed and synthesized a series of compounds derived from proline and gamma-aminobutyric acid (GABA) and tested their bioactivity in antioxidant and anti-inflammatory assays. The results showed that these compounds exhibited promising antioxidant and anti-inflammatory properties, as well as moderate inhibition of acetylcholinesterase, a key enzyme involved in neurodegeneration. The findings suggest that these compounds could be further optimized for the treatment of degenerative conditions. [Extracted from the article]

A report from Nanyang Normal University in China discusses the development of novel fluoro-substituted rivastigmine derivatives as selective AChE inhibitors for the treatment of Alzheimer's disease (AD). The researchers designed and evaluated 29 compounds through various tests, and compound 9a showed the best inhibitory potency against AChE. It also demonstrated a neuroprotective effect on cells. The study concludes that compound 9a is a promising selective AChE inhibitor for treating AD. This research has been peer-reviewed. [Extracted from the article]

A study conducted at King Abdulaziz University in Jeddah, Saudi Arabia, explored the neuroprotective effects of Astaxanthin (AST) in a mouse model of Alzheimer's disease induced by scopolamine. The study involved 36 adult male mice divided into six groups, and after 14 days, their short-term memory, hippocampus tissue, oxidative and inflammatory markers were evaluated. The results showed that AST had a beneficial impact on short-term memory, reduced acetylcholinesterase activity in the brain, exhibited neuroprotective and anti-amyloidogenic properties, and decreased pro-inflammatory markers and oxidative stress. The study suggests that AST may have therapeutic benefits against cognitive dysfunction in Alzheimer's disease. [Extracted from the article]

A recent study conducted by researchers at the Medical University of Lublin in Poland explored the effects of cannabidiol (CBD) and rivastigmine on memory impairment caused by scopolamine in mice. The study found that both CBD and rivastigmine individually improved memory in the mice, but the combination of the two compounds was even more effective in reducing cognitive impairment. These findings suggest that the combination therapy of CBD and rivastigmine could be beneficial in the treatment of cognitive disorders associated with cholinergic pathways. Further research is needed to explore the potential of this polytherapy in clinical settings. [Extracted from the article]

A recent study conducted by researchers at "Grigore T. Popa" University of Medicine and Pharmacy in Romania explored the therapeutic effects of Matricaria chamomilla extract compared to Galantamine on memory in animal models. The study found that rats treated with Matricaria chamomilla extract showed metabolic similarities to normal rats, while those treated with Galantamine showed features closer to the diseased group. Behavioral assessments also indicated that the Matricaria chamomilla extract group exhibited less anxiety and better locomotor activity compared to the Galantamine group. These findings suggest that Matricaria chamomilla extract could be a potent neuropharmacological agent against amnesia. [Extracted from the article]

A study conducted at Huazhong Agricultural University in Wuhan, China, has developed a chemo-enzymatic synthesis method for Rivastigmine, a pharmaceutical used in the treatment of Alzheimer's disease. The researchers used an engineered alcohol dehydrogenase from Lactobacillus brevis to synthesize a key chiral intermediate, and improved its catalytic activity and thermal stability through a semi-rational approach. The study successfully synthesized Rivastigmine with an overall yield of 66% and produced several efficient LbADH variants with potential applications. This research offers an efficient chemo-enzymatic route for Rivastigmine synthesis and provides valuable insights for future drug development. [Extracted from the article]

A recent report from Taibah University discusses research on Alzheimer's disease. The study focuses on the development of bis-hydrazono[1,3,4]thiadiazoles as potential anti-Alzheimer's agents. The researchers synthesized these compounds and conducted in vitro tests to assess their inhibitory activity against acetylcholinesterase, an enzyme involved in the breakdown of the neurotransmitter acetylcholine. The results showed promising inhibition activities for certain compounds, suggesting their potential as medications for Alzheimer's disease. Further research and experimentation are needed to explore the efficacy of these compounds. [Extracted from the article]

New research from the University of Aberdeen in the United Kingdom has revealed new findings on Alzheimer's disease. The study focused on the role of tau protein aggregation and cholinergic dysfunction in the disease. The researchers found that a tau aggregation inhibitor called hydromethylthionine mesylate (HMTM) showed promise as a potential treatment for reversing cholinergic deficits in a mouse model of Alzheimer's disease. However, the efficacy of HMTM was diminished when used in combination with the acetylcholinesterase inhibitor rivastigmine. The study suggests that tau accumulation may underpin the loss of cholinergic markers in the brain. [Extracted from the article]

A recent report from the Institute of Nuclear Chemistry and Technology in Warsaw, Poland discusses the use of tacrine and its derivatives as radiotracers for the diagnosis of Alzheimer's disease. Tacrine is a drug that was previously approved for Alzheimer's disease due to its ability to increase the level of acetylcholine in the central nervous system. The researchers found that radiopreparations based on tacrine or its analogues were able to cross the blood-brain barrier, while those containing a modified tacrine molecule lost this ability. Computer docking studies also revealed how these compounds bind to the active sites of cholinesterase enzymes. This research provides valuable insights into the development of diagnostic tools for Alzheimer's disease. [Extracted from the article]

A recent study conducted at Normandie University in Rouen, France, has identified potential multitarget ligands for the treatment of Alzheimer's disease. The researchers developed a series of compounds that showed potent inhibition of the enzyme eqBuChE, as well as inhibitory properties against hDYRK1A and hCLK1 kinases. The study found that structural modifications to the compounds led to selective and potent inhibitors. The researchers believe that these compounds have promising potential as drug candidates for the treatment of Alzheimer's disease. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the potential of dual tacrine derivatives as a treatment for Alzheimer's disease. These compounds act as both acetylcholinesterase inhibitors and NMDA receptor antagonists, targeting two pathophysiological pathways simultaneously. The study found that certain compounds showed promising pro-cognitive effects in rat models of cognitive deficits, improving memory acquisition and alleviating behavioral deficits. The most promising compound, K1599, demonstrated pro-cognitive efficacy in both cholinergic and glutamatergic models. Further research is needed to explore the structural and functional properties of these derivatives. [Extracted from the article]

A patent application has been filed for a method of alleviating, preventing, or treating the adverse effects of cholinesterase inhibitors, which are potential drugs for brain conditions such as Alzheimer's disease and dementia. The method involves administering an antioxidant before, simultaneously with, or after the cholinesterase inhibitor. The patent application also discusses the need for methods to alleviate the adverse effects of these inhibitors, as their systemic administration can cause various side effects. The invention aims to promote neuronal differentiation and protection while ensuring the safe use of cholinesterase inhibitors. [Extracted from the article]

A recent study conducted at Sidi Mohammed Ben Abdellah University in Fez, Morocco, explored the effectiveness of novel tacrine derivatives in treating Alzheimer's disease (AD). Tacrine was originally used as a palliative treatment for AD but had side effects on human health. The researchers used 3-dimensional quantitative structure-activity relationships (3D-QSARs) to generate models and found that certain compounds showed promise in terms of safety and molecular stability. These compounds were recommended for further study as potential treatments for AD. The study was supported by Princess Nora Bint Abdulrahman University. [Extracted from the article]

A recent report from the University of Lisbon discusses the search for new drug candidates for Alzheimer's disease (AD), which currently has no cure. The researchers designed and evaluated nine rivastigmine-indole hybrids as potential multitarget anti-AD drugs. These hybrids showed promising results in inhibiting enzymes associated with AD and demonstrated antioxidant activity. Two compounds, 5a3 and 5c3, were identified as lead compounds for further investigation as potential anti-AD drug candidates. The study also suggested that these compounds have potential oral availability. Further research is needed to explore their efficacy. [Extracted from the article]

A study conducted by the Orbeli Institute of Physiology in Yerevan, Armenia, has found that long-term consumption of sugar-rich beverages can lead to various clinical conditions, including metabolic syndrome, impaired cholinergic transmission, and cognitive decline. The researchers focused on the effects of long-term fructose consumption on changes in short-term plasticity parameters of rat brain neurons. They discovered that there were significant changes in excitatory responses and an increase in background spike activity in the fructose group. However, the administration of Galantamine, a cholinesterase inhibitor, showed a recovery tendency for these changes. The study suggests that these findings have implications for the treatment of neurodegenerative diseases. [Extracted from the article]

Researchers from the National Institute of Technology in Warangal, India have developed a mild and environmentally friendly method for synthesizing functionalized tacrine derivatives, which are central nervous system agents. The researchers used a biodegradable and reusable deep eutectic solvent to form C-C and C-N bonds, resulting in the production of unsaturated compounds with good yields. The synthesized compounds were found to be potent inhibitors of acetyl/butyrylcholinesterase and alpha-glucosidase, with some compounds showing better activity than standard drugs. This research provides valuable insights into the synthesis and evaluation of tacrine derivatives for potential therapeutic applications. [Extracted from the article]

A study conducted at Hasanuddin University in Makassar, Indonesia, has developed a new method for delivering rivastigmine nanoparticles to the brain for the treatment of Alzheimer's disease. The researchers used a combination of poly-lactid-co-glycolid acid (PLGA)-based nanoparticles and hyaluronic acid-based dissolving microneedles to effectively deliver the drug through the nasal cavity to the brain. The formulations were found to be effective in ex vivo and in vivo studies, with higher drug targeting efficiency and direct transport percentage compared to conventional administration methods. This approach shows promise as a future-novel treatment for Alzheimer's disease. [Extracted from the article]

Researchers from Zhaoqing University in China have published a new study on central nervous system agents, specifically focusing on selective butyrylcholinesterase inhibitors as potential treatments for Alzheimer's disease. The study synthesized and characterized a rivastigmine-bambuterol hybrid compound and its analogues, finding that they were more potent inhibitors of butyrylcholinesterase compared to acetylcholinesterase. The best compound in the series, MTR-3, showed high selectivity and inhibition potency, as well as the potential to permeate the blood-brain barrier and provide longer-lasting inhibition. The researchers concluded that these compounds could be used to discover novel specific butyrylcholinesterase inhibitors for Alzheimer's disease treatment. [Extracted from the article]

Researchers from the University of Concepcion in Chile have developed a sustained-release formulation of the drug rivastigmine for the treatment of Alzheimer's disease. Rivastigmine is an acetylcholinesterase inhibitor used to treat mild to moderate dementia. The researchers used polylactic co-glycolic acid (PLGA) microparticles to encapsulate the drug and achieve sustained release. The microparticles were found to be stable and effective in vitro and in vivo. This study is the first to demonstrate sustained release of rivastigmine from PLGA microparticles after intramuscular administration. [Extracted from the article]

A recent study conducted at Princess Nourah bint Abdulrahman University in Riyadh, Saudi Arabia, explored the interaction between the neurological drug rivastigmine and human insulin protein. The study aimed to understand how proteins aggregate and contribute to neurodegenerative diseases like Alzheimer's, Parkinson's, and Huntington's. The research found that rivastigmine has the ability to inhibit the fibrillation of human insulin protein and interfere with its hydrophobic domain. Molecular docking and dynamics simulation studies revealed that rivastigmine interacts with acetylcholinesterase and Ab-42, inhibiting their hydrolytic activity. This research provides insights into the mechanisms of neurological drug inhibition and may inform the development of new therapeutics for amyloidosis. [Extracted from the article]

A recent report from the University of Tabriz in Iran discusses the synthesis and characterization of a magnetic molecularly imprinted polymer (MIP) for use as a drug carrier for rivastigmine, a central nervous system agent. The researchers synthesized a magnetic MIP based on magnetic graphene oxide and polydopamine, and compared its performance to a nonimprinted polymer. Various analyses were conducted to characterize the polymers, and drug loading and release studies were performed. The results showed that the MIP exhibited controlled drug release, with the drug release mechanism being Fickian diffusion. The maximum efficiency of drug loading on the MIP was 96.44% at a drug concentration of 400 ppm. [Extracted from the article]

A recent study conducted at Jichi Medical University in Tochigi, Japan, has reported on the improper application of a rivastigmine patch to the back of the neck, which induced toxic symptoms in an 85-year-old woman with Alzheimer's disease. The woman experienced acute cholinergic syndrome, hypersalivation, anorexia, dyspnea, and vomiting. These symptoms resolved when the improper use of the patch was stopped. The research serves as a warning to physicians and pharmacists about the risks associated with the incorrect placement of rivastigmine patches. [Extracted from the article]

A research study conducted by Jiangsu Kanion Pharmaceutical Co. Ltd. in Lianyungang, China, has developed a series of OA-tacrine hybrids as potential cholinesterase inhibitors for the treatment of Alzheimer's disease (AD). The study found that certain compounds, specifically B4 and D4, demonstrated significant inhibitory activities against acetylcholinesterase (AChE) with low neurotoxicity and hepatotoxicity. These compounds showed promise as potential agents for the treatment of AD and warrant further investigation. The study was funded by the Lianyungang Postdoctoral Research Funding Program and the Education Department of Liaoning Province. [Extracted from the article]

A recent report from Charles Sturt University provides insights into vascular dementia (VaD), the second most common type of dementia after Alzheimer's disease. The report explores risk factors, pharmacological interventions, and non-pharmacotherapeutic strategies associated with VaD. Risk factors include advanced age, hypertension, diabetes, obesity, and hyperlipidemia, with emerging evidence implicating additional lifestyle and genetic factors. Pharmacotherapy for VaD focuses on managing these risk factors and includes antihypertensives, statins, antiplatelet drugs, antidiabetic agents, and cognitive enhancers. Non-pharmacotherapeutic strategies, such as diet and exercise, have shown promise in improving cognitive function and quality of life. Further research is needed to define best practices for both pharmacotherapy and non-pharmacotherapy treatments for VaD. [Extracted from the article]

Karnataka, India, Asia, Central Nervous System Agents, Cholinergic Agent, Cholinesterase Inhibitors, Dicarboxylic Acids, Drugs and Therapies, Elements, Emerging Technologies, Gases, Health and Medicine, Hydrogen, Inorganic Chemicals, Nanocarriers, Nanotechnology, Nootropic Agents, Parasympathomimetic, Pharmaceuticals, Rivastigmine Therapy, Sugar Acids, Tartrates Keywords: Karnataka; India; Asia; Central Nervous System Agents; Cholinergic Agent; Cholinesterase Inhibitors; Dicarboxylic Acids; Drugs and Therapies; Elements; Emerging Technologies; Gases; Health and Medicine; Hydrogen; Inorganic Chemicals; Nanocarriers; Nanotechnology; Nootropic Agents; Parasympathomimetic; Pharmaceuticals; Rivastigmine Therapy; Sugar Acids; Tartrates EN Karnataka India Asia Central Nervous System Agents Cholinergic Agent Cholinesterase Inhibitors Dicarboxylic Acids Drugs and Therapies Elements Emerging Technologies Gases Health and Medicine Hydrogen Inorganic Chemicals Nanocarriers Nanotechnology Nootropic Agents Parasympathomimetic Pharmaceuticals Rivastigmine Therapy Sugar Acids Tartrates 1552 1552 1 10/03/23 20231006 NES 231006 2023 OCT 6 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Current study results on Nanotechnology - Nanocarriers have been published. [Extracted from the article]

Microtubule-affinity regulating kinase 4 (MARK4) is an evolutionarily conserved Ser-Thr (S/T) kinase that phosphorylates tau and microtubule-associated proteins, thus playing a critical role in AD pathology." Keywords: Alzheimer Disease; Brain Diseases and Conditions; Central Nervous System Agents; Central Nervous System Diseases and Conditions; Cholinesterase Inhibitors; Dementia; Drugs and Therapies; Enzymes and Coenzymes; Galantamine Therapy; Health and Medicine; Kinase; Neurodegenerative Diseases and Conditions; Nootropic Agents; Parasympathomimetic; Pharmaceuticals; Tauopathies EN Alzheimer Disease Brain Diseases and Conditions Central Nervous System Agents Central Nervous System Diseases and Conditions Cholinesterase Inhibitors Dementia Drugs and Therapies Enzymes and Coenzymes Galantamine Therapy Health and Medicine Kinase Neurodegenerative Diseases and Conditions Nootropic Agents Parasympathomimetic Pharmaceuticals Tauopathies 1734 1734 1 10/03/23 20231006 NES 231006 2023 OCT 6 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Alzheimer disease. [Extracted from the article]

New Delhi, India, Asia, Acute-Phase Proteins, Alzheimer Disease, Beta-Globulins, Blood Proteins, Brain Diseases and Conditions, Carrier Proteins, Central Nervous System Agents, Central Nervous System Diseases and Conditions, Cholinergic Agent, Cholinesterase Inhibitors, Dementia, Drugs and Therapies, Health and Medicine, Iron-Binding Proteins, Neurodegenerative Diseases and Conditions, Parasympathomimetic, Pharmaceuticals, Proteins, Rivastigmine Therapy, Tauopathies, Transferrin, Nootropic Agents Keywords: New Delhi; India; Asia; Acute-Phase Proteins; Alzheimer Disease; Beta-Globulins; Blood Proteins; Brain Diseases and Conditions; Carrier Proteins; Central Nervous System Agents; Central Nervous System Diseases and Conditions; Cholinergic Agent; Cholinesterase Inhibitors; Dementia; Drugs and Therapies; Health and Medicine; Iron-Binding Proteins; Neurodegenerative Diseases and Conditions; Nootropic Agents; Parasympathomimetic; Pharmaceuticals; Proteins; Rivastigmine Therapy; Tauopathies; Transferrin EN New Delhi India Asia Acute-Phase Proteins Alzheimer Disease Beta-Globulins Blood Proteins Brain Diseases and Conditions Carrier Proteins Central Nervous System Agents Central Nervous System Diseases and Conditions Cholinergic Agent Cholinesterase Inhibitors Dementia Drugs and Therapies Health and Medicine Iron-Binding Proteins Neurodegenerative Diseases and Conditions Nootropic Agents Parasympathomimetic Pharmaceuticals Proteins Rivastigmine Therapy Tauopathies Transferrin 2651 2651 1 09/04/23 20230908 NES 230908 2023 SEP 8 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Researchers detail new data in Neurodegenerative Diseases and Conditions - Alzheimer Disease. [Extracted from the article]

Keywords for this news article include: St. Petersburg, Russia, Obesity, Fitness and Wellness, Institute of Experimental Medicine. St. Petersburg, Russia, Obesity Fitness and Wellness Keywords: St. Petersburg; Russia; Obesity Fitness and Wellness EN St. Petersburg Russia Obesity Fitness and Wellness 2408 2408 1 09/04/23 20230908 NES 230908 2023 SEP 8 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Data detailed on Obesity, Fitness and Wellness have been presented. [Extracted from the article]

Alzheimer Disease, Brain Diseases and Conditions, Central Nervous System Agents, Central Nervous System Diseases and Conditions, Cholinesterase Inhibitors, Dementia, Drugs and Therapies, Health and Medicine, Neurodegenerative Diseases and Conditions, Parasympathomimetic, Pharmaceuticals, Risk and Prevention, Tacrine Therapy, Tauopathies, Nootropic Agents Keywords: Alzheimer Disease; Brain Diseases and Conditions; Central Nervous System Agents; Central Nervous System Diseases and Conditions; Cholinesterase Inhibitors; Dementia; Drugs and Therapies; Health and Medicine; Neurodegenerative Diseases and Conditions; Nootropic Agents; Parasympathomimetic; Pharmaceuticals; Risk and Prevention; Tacrine Therapy; Tauopathies EN Alzheimer Disease Brain Diseases and Conditions Central Nervous System Agents Central Nervous System Diseases and Conditions Cholinesterase Inhibitors Dementia Drugs and Therapies Health and Medicine Neurodegenerative Diseases and Conditions Nootropic Agents Parasympathomimetic Pharmaceuticals Risk and Prevention Tacrine Therapy Tauopathies 1012 1012 1 08/28/23 20230901 NES 230901 2023 SEP 1 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- New research on Alzheimer disease is the subject of a new report. [Extracted from the article]

Treated hyperoxic group showed a significant increase of choline acetyl transferase (ChAT) expression and a decrease of acetyl choline esterase activity, thus increasing acetyl choline levels in hyperoxia environment. Keywords: Brain Diseases and Conditions; Brain Injury; Central Nervous System Agents; Central Nervous System Diseases and Conditions; Choline; Cholinesterase Inhibitors; Craniocerebral Trauma; Diet and Nutrition; Drugs and Therapies; Enzymes and Coenzymes; Esterases; Ethanolamines; Galantamine Therapy; Health and Medicine; Hyperoxia; Micronutrient; Nootropic Agents; Parasympathomimetic; Pharmaceuticals; Quaternary Ammonium Compounds; Trimethyl Ammonium Compounds EN Brain Diseases and Conditions Brain Injury Central Nervous System Agents Central Nervous System Diseases and Conditions Choline Cholinesterase Inhibitors Craniocerebral Trauma Diet and Nutrition Drugs and Therapies Enzymes and Coenzymes Esterases Ethanolamines Galantamine Therapy Health and Medicine Hyperoxia Micronutrient Nootropic Agents Parasympathomimetic Pharmaceuticals Quaternary Ammonium Compounds Trimethyl Ammonium Compounds 2138 2138 1 07/10/23 20230714 NES 230714 2023 JUL 14 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- New research on brain injury is the subject of a new report. [Extracted from the article]

Keywords: Adrenergic Agent; Adrenergic Uptake Inhibitor; CNS Stimulants; Carbocyclic Acids; Central Nervous System Agents; Central Nervous System Stimulants; Dopamine Uptake Inhib; Drugs and Therapies; Health and Medicine; Methylphenidate; Methylphenidate Therapy; Norepinephrine-Dopamine Reuptake Inhibitors; Pharmaceuticals; Phenylacetates; Psychotherapeutic Agents; University of Cambridge EN Adrenergic Agent Adrenergic Uptake Inhibitor CNS Stimulants Carbocyclic Acids Central Nervous System Agents Central Nervous System Stimulants Dopamine Uptake Inhib Drugs and Therapies Health and Medicine Methylphenidate Methylphenidate Therapy Norepinephrine-Dopamine Reuptake Inhibitors Pharmaceuticals Phenylacetates Psychotherapeutic Agents University of Cambridge 102 102 1 06/26/23 20230627 NES 230627 2023 JUN 30 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- New research from the University of Cambridge and the University of Melbourne, published in Science Advances, shows neurotypical workers and students taking cognitive enhancers, or "smart" drugs, may actually be inhibiting their performance and productivity. Drugs such as methylphenidate, sold under the brand name Ritalin among others, are commonly prescribed for attention deficit hyperactivity disorder (ADHD), but are also taken by those without a diagnosis, in the belief that the drugs will enhance focus and cognitive performance. Adrenergic Agent, Adrenergic Uptake Inhibitor, CNS Stimulants, Carbocyclic Acids, Central Nervous System Agents, Central Nervous System Stimulants, Dopamine Uptake Inhib, Drugs and Therapies, Health and Medicine, Methylphenidate Therapy, Norepinephrine-Dopamine Reuptake Inhibitors, Pharmaceuticals, Phenylacetates, Methylphenidate, Psychotherapeutic Agents, University of Cambridge. [Extracted from the article]

The news reporters obtained a quote from the research from North-Eastern Hill University, "Furthermore, the modulatory effect of these nano-conjugates toward the in-vitro catalytic activity of the neurodegenerative enzyme acetylcholinesterase (AChE) is also quantified. Keywords: Shillong; India; Asia; Acetylcholine; Acetylcholinesterase; Biogenic Amines; Central Nervous System Agents; Cholinesterase Inhibitors; Cholinesterases; Drugs and Therapies; Enzymes and Coenzymes; Health and Medicine; Hydrolases; Nootropic Agents; Parasympathomimetic; Pharmaceuticals; Tacrine Therapy EN Shillong India Asia Acetylcholine Acetylcholinesterase Biogenic Amines Central Nervous System Agents Cholinesterase Inhibitors Cholinesterases Drugs and Therapies Enzymes and Coenzymes Health and Medicine Hydrolases Nootropic Agents Parasympathomimetic Pharmaceuticals Tacrine Therapy 2496 2496 1 06/19/23 20230623 NES 230623 2023 JUN 23 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Data detailed on Drugs and Therapies - Central Nervous System Agents have been presented. [Extracted from the article]

The present theoretical-experimental work improves the drug's residence time without reducing the inhibition effect, thus providing a crucial breakthrough for modifying the inhibitor of AChE with better kinetic behavior." Kaifeng, People's Republic of China, Asia, Acetylcholine, Acetylcholinesterase, Biogenic Amines, Central Nervous System Agents, Cholinesterase Inhibitors, Cholinesterases, Drugs and Therapies, Enzymes and Coenzymes, Galantamine Therapy, Health and Medicine, Hydrolases, Parasympathomimetic, Pharmaceuticals, Nootropic Agents Keywords: Kaifeng; People's Republic of China; Asia; Acetylcholine; Acetylcholinesterase; Biogenic Amines; Central Nervous System Agents; Cholinesterase Inhibitors; Cholinesterases; Drugs and Therapies; Enzymes and Coenzymes; Galantamine Therapy; Health and Medicine; Hydrolases; Nootropic Agents; Parasympathomimetic; Pharmaceuticals EN Kaifeng People's Republic of China Asia Acetylcholine Acetylcholinesterase Biogenic Amines Central Nervous System Agents Cholinesterase Inhibitors Cholinesterases Drugs and Therapies Enzymes and Coenzymes Galantamine Therapy Health and Medicine Hydrolases Nootropic Agents Parasympathomimetic Pharmaceuticals 1530 1530 1 05/02/23 20230505 NES 230505 2023 MAY 5 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Data detailed on Drugs and Therapies - Central Nervous System Agents have been presented. [Extracted from the article]

Kosice, Slovakia, Europe, Central Nervous System Agents, Cholinesterase Inhibitors, Drugs and Therapies, Health and Medicine, Parasympathomimetic, Pharmaceuticals, Tacrine Therapy, Nootropic Agents Keywords: Kosice; Slovakia; Europe; Central Nervous System Agents; Cholinesterase Inhibitors; Drugs and Therapies; Health and Medicine; Nootropic Agents; Parasympathomimetic; Pharmaceuticals; Tacrine Therapy EN Kosice Slovakia Europe Central Nervous System Agents Cholinesterase Inhibitors Drugs and Therapies Health and Medicine Nootropic Agents Parasympathomimetic Pharmaceuticals Tacrine Therapy 919 919 1 04/17/23 20230421 NES 230421 2023 APR 21 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- New research on Drugs and Therapies - Central Nervous System Agents is the subject of a report. [Extracted from the article]

Keywords: Alzheimer Disease; Brain Diseases and Conditions; Central Nervous System Agents; Central Nervous System Diseases and Conditions; Cholinesterase Inhibitors; Dementia; Drugs and Therapies; Emerging Technologies; Galantamine Therapy; Health and Medicine; Nanoparticles; Nanotechnology; Neurodegenerative Diseases and Conditions; Nootropic Agents; Parasympathomimetic; Pharmaceuticals; Tauopathies EN Alzheimer Disease Brain Diseases and Conditions Central Nervous System Agents Central Nervous System Diseases and Conditions Cholinesterase Inhibitors Dementia Drugs and Therapies Emerging Technologies Galantamine Therapy Health and Medicine Nanoparticles Nanotechnology Neurodegenerative Diseases and Conditions Nootropic Agents Parasympathomimetic Pharmaceuticals Tauopathies 1778 1778 1 03/23/23 20230324 NES 230324 2023 MAR 24 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Alzheimer disease. GH release profiles in PBS at 37 °C were obtained for both types of NPs, and it was found that the GH-loaded chitosan NPs allowed the prolonged release of the incorporated drug for a period of 8 h, while the complex GH-loaded chitosan/alginate NPs released the incorporated GH faster. [Extracted from the article]

Keywords: Cairo; Egypt; Africa; Alzheimer Disease; Bacterial Polysaccharides; Bacterial Toxins; Biological Factors; Brain Diseases and Conditions; Central Nervous System Agents; Central Nervous System Diseases and Conditions; Cholinesterase Inhibitors; Dementia; Drugs and Therapies; Emerging Technologies; Endotoxins; Galantamine Therapy; Health and Medicine; Lipopolysaccharides; Nanosprays; Nanotechnology; Neurodegenerative Diseases and Conditions; Nootropic Agents; Parasympathomimetic; Pharmaceuticals; Tauopathies EN Cairo Egypt Africa Alzheimer Disease Bacterial Polysaccharides Bacterial Toxins Biological Factors Brain Diseases and Conditions Central Nervous System Agents Central Nervous System Diseases and Conditions Cholinesterase Inhibitors Dementia Drugs and Therapies Emerging Technologies Endotoxins Galantamine Therapy Health and Medicine Lipopolysaccharides Nanosprays Nanotechnology Neurodegenerative Diseases and Conditions Nootropic Agents Parasympathomimetic Pharmaceuticals Tauopathies 574 574 1 03/23/23 20230317 NES 230317 2023 MAR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Neurodegenerative Diseases and Conditions - Alzheimer Disease. Cairo, Egypt, Africa, Alzheimer Disease, Bacterial Polysaccharides, Bacterial Toxins, Biological Factors, Brain Diseases and Conditions, Central Nervous System Agents, Central Nervous System Diseases and Conditions, Cholinesterase Inhibitors, Dementia, Drugs and Therapies, Emerging Technologies, Endotoxins, Galantamine Therapy, Health and Medicine, Lipopolysaccharides, Nanosprays, Nanotechnology, Neurodegenerative Diseases and Conditions, Nootropic Agents, Parasympathomimetic, Pharmaceuticals, Tauopathies. [Extracted from the article]

Keywords: Acetylcholine; Acetylcholinesterase; Biogenic Amines; Central Nervous System Agents; Cholinesterase Inhibitors; Cholinesterases; Drugs and Therapies; Enzymes and Coenzymes; Galantamine Therapy; Health and Medicine; Hydrolases; Molecular Modeling; Nootropic Agents; Parasympathomimetic; Pharmaceuticals EN Acetylcholine Acetylcholinesterase Biogenic Amines Central Nervous System Agents Cholinesterase Inhibitors Cholinesterases Drugs and Therapies Enzymes and Coenzymes Galantamine Therapy Health and Medicine Hydrolases Molecular Modeling Nootropic Agents Parasympathomimetic Pharmaceuticals 1251 1251 1 03/24/23 20230228 NES 230228 2023 MAR 3 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on central nervous system agents. Acetylcholine, Acetylcholinesterase, Biogenic Amines, Central Nervous System Agents, Cholinesterase Inhibitors, Cholinesterases, Drugs and Therapies, Enzymes and Coenzymes, Galantamine Therapy, Health and Medicine, Hydrolases, Molecular Modeling, Nootropic Agents, Parasympathomimetic, Pharmaceuticals. [Extracted from the article]

Keywords: Jackson; State:Mississippi; United States; North and Central America; Obesity Fitness and Wellness; Alcohols; Drugs and Therapies; Ethanol; Ethanolamines; Health and Medicine; Pharmacotherapy; Therapy EN Jackson State:Mississippi United States North and Central America Obesity Fitness and Wellness Alcohols Drugs and Therapies Ethanol Ethanolamines Health and Medicine Pharmacotherapy Therapy 1158 1158 1 03/24/23 20230217 NES 230217 2023 FEB 17 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Data detailed on Obesity, Fitness and Wellness have been presented. Behavior then was extinguished (Phase 2) by omitting the ethanol solution yet retaining the ethanol-paired stimulus lights. [Extracted from the article]